Forget Wegovy and Zepbound. Never mind CagriSema, and even retatrutide. The latest big name in obesity is eloraTZP. Data ...
Varda Space Industries raises a $251M Series D, valuing it at $1.6B, to advance space-based drug manufacturing using low ...
Merck's tulisokibart showed mid-stage success in hidradenitis suppurativa, with 72% high-dose patients seeing 50%+ abscess ...
Beam Therapeutics sued YolTech's Yuxuan Wu & Zi Jun Wang and Serapha Bio for allegedly stealing trade secrets related to ...
Zealand and Roche's petrelintide peaks at 10.7% weight loss at its middle dose in Ph2, trailing Lilly's eloralintide at 20.1% ...
UniQure's shares were rocked Tuesday morning after the company revealed its experimental Huntington’s disease gene therapy ...
NCI director Ned Sharpless as MD and Andrew Witty as chairman, while raising a $100M second opportunities fund.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results